Abstract
We conducted a prospective study to investigate access to treatment in hepatitis C in 268 prisoners. Hepatitis C positivity had been known for 182 prisoners previously and 19 reported previous attempts to treat (10%). In comparison, during our study, 86/268 prisoners (32%) started therapy (P < 0.0001). They represented 41% of 211 prisoners with a positive viral load. In the genotype 2 or 3 group, 46 prisoners (50%) started therapy versus 40 prisoners (33%) with other genotypes (P = 0.01). This difference was due to prisoners waiting for liver biopsy. On an intention to treat basis, 45 prisoners (52%) achieved sustained virological response 6 months after the end of therapy. We conclude that a stay in prison is an effective opportunity to treat a group of hepatitis C patients which otherwise have very limited access to therapy.
Similar content being viewed by others
References
EASL International Consensus Conference on hepatitis C. J Hepatol. 1999;31(suppl 1):3–8. doi:10.1016/S0168-8278(99)80367-5.
Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–562. doi:10.1056/NEJM199908193410802.
Remy AJ. Hepatitis C in prison settings: screening and therapy are improving. Presse Med. 2006;35:1249–1254. doi:10.1016/S0755-4982(06)74797-2.
Claudon-Charpentier A, Hoibian M, Glasser P, Lalanne H, Pasquali JL. Drug addicted inmates of the Elsau prison, Strasbourg, France. Rev Med Interne. 2000;21:505–509. doi:10.1016/S0248-8663(00)89225-5.
Holsen DS, Harthug S, Myrmel H. Prevalence of antibodies to hepatitis C virus and association with intravenous drug abuse and tattooing in a national prison in Norway. Eur J Clin Microbiol Infect Dis. 1993;12:673–676. doi:10.1007/BF02009378.
Allwright S, Bradley F, Long J, Barry J, Thornton L, Parry JV. Prevalence of antibodies to hepatitis B, hepatitis C and HIV and risk factors in Irish prisoners: result of a national cross sectional survey. BMJ.. 2000;321:78–82. doi:10.1136/bmj.321.7253.78.
Gore SM, Bird AG, Cameron SO, Hutchinson SJ, Burns SM, Goldberg DJ. Prevalence of hepatitis C in prison. Q J Med. 1999;92:25–32.
Hedouin V, Gosset D. Hepatitis C virus infection in a prison population. Gastroenterol Clin Biol. 1998;22:55–58.
Skipper C, Guy JM, Parkes J, Roderick P, Rosenberg WM. Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy. Gut. 2003;52:1500–1504. doi:10.1136/gut.52.10.1500.
Morrison DS, Gilchrist G. Prison admission health screening as a measure of health needs. Health Bull (Edinb). 2001;59:114–119.
Christensen PB, Krarup HB, Niesters HGM, Norder H, Georgsen J. Prevalence and incidence of bloodborne viruses among Danish prisoners. Eur J Epidemiol. 2000;16:1043–1049. doi:10.1023/A:1010833917242.
Fox RK, Currie SL, Evans J, et al. Hepatitis C virus infection among prisoners in the California state correctional system. Clin Infect Dis. 2005;41:177–186. doi:10.1086/430913.
Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003;138:187–190.
Sterling RK, Hofmann CM, Luketic VA, et al. Treatment of chronic hepatitis C virus in the Virginia department of corrections: can compliance overcome racial differences to response? Am J Gastroenterol. 2004;99:866–872. doi:10.1111/j.1572-0241.2004.30310.x.
Blanchet E, Defossez G, Verneau A, Ingrand I, Silvain C, Beauchant M. Epidemiology and management of care of hepatitis C infection in the Poitou-Charentes region in 1997 and 2000. Gastroenterol Clin Biol. 2003;27:1026–1030.
Hatem C, Minello A, Bresson-Hadni S, et al. Is the management of hepatitis C patients appropriate? A population-based study. Aliment Pharmacol Ther. 2005;21:1007–1015. doi:10.1111/j.1365-2036.2005.02393.x.
Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136:288–292.
Narasimhan G, Sargios TN, Kalakuntla R, et al. Treatment rates in patients with chronic hepatitis C after liver biopsy. J Viral Hepat. 2006;13:783–786. doi:10.1111/j.1365-2893.2006.00763.x.
Shaheen AAM, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology. 2007;46:912–921. doi:10.1002/hep.21835.
Bini EJ, Bräu N, Currie S, et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol. 2005;100:1772–1779. doi:10.1111/j.1572-0241.2005.41860.x.
Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kent Kwoh C. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007;56:385–389. doi:10.1136/gut.2006.099150.
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982. doi:10.1056/NEJMoa020047.
Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side-effects. Hepatology. 2007;46:991–998. doi:10.1002/hep.21791.
Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998;28:805–809. doi:10.1002/hep.510280330.
McGovern BH, Wurcel A, Kim AY, et al. Acute hepatitis C virus infection in incarcerated injection drug users. Clin Infect Dis. 2006;42:1663–1670. doi:10.1086/504327.
Acknowledgments
The authors would like to thank the nursing, GP, and psychiatric teams of Schrassig prison infirmary, Luxembourg. Without their infallible commitment, this study in particular, and taking care of prisoners with hepatitis C in general, would not have been possible. Special thanks to Professor Christine SILVAIN from the Hepatogastroenterology Unit of the University Hospital in Poitiers, France, for her invaluable help with the design of the study and the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Strock, P., Mossong, J., Hawotte, K. et al. Access to Treatment of Hepatitis C in Prison Inmates. Dig Dis Sci 54, 1325–1330 (2009). https://doi.org/10.1007/s10620-008-0483-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-008-0483-8